Cargando…
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-RE...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962711/ https://www.ncbi.nlm.nih.gov/pubmed/36835891 http://dx.doi.org/10.3390/jcm12041356 |
_version_ | 1784896073482895360 |
---|---|
author | Semo, Dilvin Obergassel, Julius Dorenkamp, Marc Hemling, Pia Strutz, Jasmin Hiden, Ursula Müller, Nicolle Müller, Ulrich Alfons Zulfikar, Sajan Ahmad Godfrey, Rinesh Waltenberger, Johannes |
author_facet | Semo, Dilvin Obergassel, Julius Dorenkamp, Marc Hemling, Pia Strutz, Jasmin Hiden, Ursula Müller, Nicolle Müller, Ulrich Alfons Zulfikar, Sajan Ahmad Godfrey, Rinesh Waltenberger, Johannes |
author_sort | Semo, Dilvin |
collection | PubMed |
description | Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG trial). Since SGLT-2 is known to be expressed on cells other than the kidney cells, we investigated the potential ability of empagliflozin to regulate glucose transport and alleviate hyperglycaemia-induced dysfunction of these cells. Methods: Primary human monocytes were isolated from the peripheral blood of T2DM patients and healthy individuals. Primary human umbilical vein endothelial cells (HUVECs) and primary human coronary artery endothelial cells (HCAECs), and fetoplacental endothelial cells (HPECs) were used as the EC model cells. Cells were exposed to hyperglycaemic conditions in vitro in 40 ng/mL or 100 ng/mL empagliflozin. The expression levels of the relevant molecules were analysed by RT-qPCR and confirmed by FACS. Glucose uptake assays were carried out with a fluorescent derivative of glucose, 2-NBDG. Reactive oxygen species (ROS) accumulation was measured using the H(2)DFFDA method. Monocyte and endothelial cell chemotaxis were measured using modified Boyden chamber assays. Results: Both primary human monocytes and endothelial cells express SGLT-2. Hyperglycaemic conditions did not significantly alter the SGLT-2 levels in monocytes and ECs in vitro or in T2DM conditions. Glucose uptake assays carried out in the presence of GLUT inhibitors revealed that SGLT-2 inhibition very mildly, but not significantly, suppressed glucose uptake by monocytes and endothelial cells. However, we detected the significant suppression of hyperglycaemia-induced ROS accumulation in monocytes and ECs when empagliflozin was used to inhibit SGLT-2 function. Hyperglycaemic monocytes and endothelial cells readily exhibited impaired chemotaxis behaviour. The co-treatment with empagliflozin reversed the PlGF-1 resistance phenotype of hyperglycaemic monocytes. Similarly, the blunted VEGF-A responses of hyperglycaemic ECs were also restored by empagliflozin, which could be attributed to the restoration of the VEGFR-2 receptor levels on the EC surface. The induction of oxidative stress completely recapitulated most of the aberrant phenotypes exhibited by hyperglycaemic monocytes and endothelial cells, and a general antioxidant N-acetyl-L-cysteine (NAC) was able to mimic the effects of empagliflozin. Conclusions: This study provides data indicating the beneficial role of empagliflozin in reversing hyperglycaemia-induced vascular cell dysfunction. Even though both monocytes and endothelial cells express functional SGLT-2, SGLT-2 is not the primary glucose transporter in these cells. Therefore, it seems likely that empagliflozin does not directly prevent hyperglycaemia-mediated enhanced glucotoxicity in these cells by inhibiting glucose uptake. We identified the reduction of oxidative stress by empagliflozin as a primary reason for the improved function of monocytes and endothelial cells in hyperglycaemic conditions. In conclusion, empagliflozin reverses vascular cell dysfunction independent of glucose transport but could partially contribute to its beneficial cardiovascular effects. |
format | Online Article Text |
id | pubmed-9962711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99627112023-02-26 The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms Semo, Dilvin Obergassel, Julius Dorenkamp, Marc Hemling, Pia Strutz, Jasmin Hiden, Ursula Müller, Nicolle Müller, Ulrich Alfons Zulfikar, Sajan Ahmad Godfrey, Rinesh Waltenberger, Johannes J Clin Med Article Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG trial). Since SGLT-2 is known to be expressed on cells other than the kidney cells, we investigated the potential ability of empagliflozin to regulate glucose transport and alleviate hyperglycaemia-induced dysfunction of these cells. Methods: Primary human monocytes were isolated from the peripheral blood of T2DM patients and healthy individuals. Primary human umbilical vein endothelial cells (HUVECs) and primary human coronary artery endothelial cells (HCAECs), and fetoplacental endothelial cells (HPECs) were used as the EC model cells. Cells were exposed to hyperglycaemic conditions in vitro in 40 ng/mL or 100 ng/mL empagliflozin. The expression levels of the relevant molecules were analysed by RT-qPCR and confirmed by FACS. Glucose uptake assays were carried out with a fluorescent derivative of glucose, 2-NBDG. Reactive oxygen species (ROS) accumulation was measured using the H(2)DFFDA method. Monocyte and endothelial cell chemotaxis were measured using modified Boyden chamber assays. Results: Both primary human monocytes and endothelial cells express SGLT-2. Hyperglycaemic conditions did not significantly alter the SGLT-2 levels in monocytes and ECs in vitro or in T2DM conditions. Glucose uptake assays carried out in the presence of GLUT inhibitors revealed that SGLT-2 inhibition very mildly, but not significantly, suppressed glucose uptake by monocytes and endothelial cells. However, we detected the significant suppression of hyperglycaemia-induced ROS accumulation in monocytes and ECs when empagliflozin was used to inhibit SGLT-2 function. Hyperglycaemic monocytes and endothelial cells readily exhibited impaired chemotaxis behaviour. The co-treatment with empagliflozin reversed the PlGF-1 resistance phenotype of hyperglycaemic monocytes. Similarly, the blunted VEGF-A responses of hyperglycaemic ECs were also restored by empagliflozin, which could be attributed to the restoration of the VEGFR-2 receptor levels on the EC surface. The induction of oxidative stress completely recapitulated most of the aberrant phenotypes exhibited by hyperglycaemic monocytes and endothelial cells, and a general antioxidant N-acetyl-L-cysteine (NAC) was able to mimic the effects of empagliflozin. Conclusions: This study provides data indicating the beneficial role of empagliflozin in reversing hyperglycaemia-induced vascular cell dysfunction. Even though both monocytes and endothelial cells express functional SGLT-2, SGLT-2 is not the primary glucose transporter in these cells. Therefore, it seems likely that empagliflozin does not directly prevent hyperglycaemia-mediated enhanced glucotoxicity in these cells by inhibiting glucose uptake. We identified the reduction of oxidative stress by empagliflozin as a primary reason for the improved function of monocytes and endothelial cells in hyperglycaemic conditions. In conclusion, empagliflozin reverses vascular cell dysfunction independent of glucose transport but could partially contribute to its beneficial cardiovascular effects. MDPI 2023-02-08 /pmc/articles/PMC9962711/ /pubmed/36835891 http://dx.doi.org/10.3390/jcm12041356 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Semo, Dilvin Obergassel, Julius Dorenkamp, Marc Hemling, Pia Strutz, Jasmin Hiden, Ursula Müller, Nicolle Müller, Ulrich Alfons Zulfikar, Sajan Ahmad Godfrey, Rinesh Waltenberger, Johannes The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms |
title | The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms |
title_full | The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms |
title_fullStr | The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms |
title_full_unstemmed | The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms |
title_short | The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms |
title_sort | sodium-glucose co-transporter 2 (sglt2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose transport-independent but redox-dependent mechanisms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962711/ https://www.ncbi.nlm.nih.gov/pubmed/36835891 http://dx.doi.org/10.3390/jcm12041356 |
work_keys_str_mv | AT semodilvin thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT obergasseljulius thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT dorenkampmarc thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT hemlingpia thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT strutzjasmin thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT hidenursula thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT mullernicolle thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT mullerulrichalfons thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT zulfikarsajanahmad thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT godfreyrinesh thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT waltenbergerjohannes thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT semodilvin sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT obergasseljulius sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT dorenkampmarc sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT hemlingpia sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT strutzjasmin sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT hidenursula sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT mullernicolle sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT mullerulrichalfons sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT zulfikarsajanahmad sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT godfreyrinesh sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms AT waltenbergerjohannes sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms |